Related Experiment Video
Updated: May 31, 2025
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
8.9K
A Review of Therapies for Clostridioides difficile Infection
1Department of Pharmacy, Keck Medical Center, University of Southern California, Los Angeles, CA 90033, USA.
Antibiotics (Basel, Switzerland)
|January 25, 2025
Summary
Clostridioides difficile infection (CDI) is a major public health concern. This review provides evidence-based recommendations for optimal treatment and prevention strategies to combat this healthcare-associated infection.
Area of Science:
- Infectious Diseases
- Public Health
- Microbiology
Background:
- Clostridioides difficile is a significant threat, impacting half a million US patients annually.
- Despite prevention efforts, Clostridioides difficile infection (CDI) remains a leading healthcare-associated infection.
- CDI imposes substantial clinical, social, and economic burdens.
Purpose of the Study:
- To provide optimal and timely therapy recommendations for Clostridioides difficile infection (CDI).
- To offer evidence-based treatment and prevention strategies for CDI.
Main Methods:
- A systematic literature review was conducted.
- Evidence was synthesized to formulate treatment recommendations.
Main Results:
- The review identified key evidence for CDI treatment and prevention.
- Recommendations are based on the available scientific literature.
Conclusions:
- Optimal and timely therapy is crucial for managing Clostridioides difficile infection (CDI).
- This systematic review provides a foundation for evidence-based clinical practice guidelines for CDI.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
106
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
106
01:17Drugs for Treatment of Diarrhea-Predominant IBS
142
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
142
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
106
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
106
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:21Drugs for Treatment of Constipation-Predominant IBS
131
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
131
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95